Skip to content
ATLAS PREP HQ
Growth Hormone

Tesamorelin

Synthetic stabilized growth hormone-releasing hormone analogue

GHRH-analog research with human clinical data on growth-hormone signaling and visceral adipose tissue.

Strong Human Evidence

Route

Subcutaneous into the abdomen, rotating sites, for approved products.

Common format

10 mg vial

Research focus

HIV lipodystrophy

Evidence level

Strong Human Evidence

Typical cycle

Ongoing / long-term

Growth Hormone research motifGrowth Hormone

Tesamorelin in 30 seconds

Atlas Fast Read

What it is

Synthetic stabilized growth hormone-releasing hormone analogue

Why people care

GHRH-analog research with human clinical data on growth-hormone signaling and visceral adipose tissue.

Human evidence

Strong Human Evidence — Substantial randomized or late-phase human evidence with clinically meaningful outcomes, and/or well-established clinical use relevant to the stated claim.

Biggest misconception

Evidence is indication-specific. Its role outside HIV-associated lipodystrophy, long-term effects of sustained IGF-1 elevation, durability after discontinuation, and cancer-risk management remain important uncertainties.

Bottom line

Tesamorelin is evidence-based for a narrow, important indication: excess visceral abdominal fat in HIV-associated lipodystrophy.

Overview

What is Tesamorelin?

Tesamorelin is synthetic stabilized growth hormone-releasing hormone analogue. GHRH-analog research with human clinical data on growth-hormone signaling and visceral adipose tissue.

Tesamorelin was developed as a stabilized GHRH analogue and received U.S. approval in 2010 for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.

Mechanism

How it works

Activates pituitary GHRH receptors to increase endogenous GH pulses and IGF-1. In HIV lipodystrophy, this signaling preferentially reduces visceral adipose tissue without being a general weight-loss drug.

Research areas

HIV lipodystrophyvisceral adipose tissueGH/IGF-1 physiologyliver-fat research

Evidence

What does the evidence actually say?

Strong Human Evidence

Substantial randomized or late-phase human evidence with clinically meaningful outcomes, and/or well-established clinical use relevant to the stated claim.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

Tesamorelin has strong randomized human evidence and FDA approval for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. That evidence does not establish it as a general obesity, bodybuilding, or longevity drug.

Preclinical evidence

Preclinical GHRH biology was well established before human development. Randomized human trials now provide direct evidence for the approved HIV-lipodystrophy indication.

Knowledge gaps

Evidence is indication-specific. Its role outside HIV-associated lipodystrophy, long-term effects of sustained IGF-1 elevation, durability after discontinuation, and cancer-risk management remain important uncertainties.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Current U.S. formulations differ: FDA labeling lists Egrifta WR 1.28 mg SC once daily and Egrifta SV 1.4 mg SC once daily; the older 2 mg/day convention and the community 1→2 mg research-vial titration should not be substituted for the labeled formulation.

Frequency

Once daily.

Timing

Label does not require a performance-specific clock time; community sources commonly places dosing in the evening.

Route

Subcutaneous into the abdomen, rotating sites, for approved products.

Cycle length

Ongoing / long-term

Reconstitution

Product-specific and not interchangeable. Egrifta WR and Egrifta SV use different vial strengths, diluents, concentrations and doses; follow the exact FDA label.

Storage

Product-specific. Egrifta WR and SV have different post-reconstitution handling; follow the exact labeled formulation instructions.

Monitoring

IGF-1, fasting glucose/HbA1c, edema/arthralgia, hypersensitivity and evidence of malignancy recurrence. Tesamorelin is contraindicated with active malignancy and disruption of the hypothalamic-pituitary axis.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Labeled effects include injection-site reactions, arthralgia/myalgia, peripheral edema and hypersensitivity. IGF-1 can rise substantially, and glucose intolerance/diabetes can worsen.

Contraindications

Current U.S. tesamorelin labeling contraindicates active malignancy, pregnancy, disruption of the hypothalamic-pituitary axis and hypersensitivity to tesamorelin/mannitol. Product-specific labeling should control.

Interactions

GH/IGF signaling can alter glucose control, so insulin and other glucose-lowering therapy may require closer monitoring. Glucocorticoids can blunt GH effects; thyroid status can influence response. Formal interaction data are limited for research secretagogues.

Stacks

Common stacks

Tesamorelin alone for its labeled indication

The best-supported use is the approved single-agent regimen for HIV-associated lipodystrophy.

Do not infer that combining it with other GH secretagogues or weight-loss drugs is proven.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

Tesamorelin is evidence-based for a narrow, important indication: excess visceral abdominal fat in HIV-associated lipodystrophy. Atlas would not turn that into proof for general fat loss, bodybuilding, or anti-aging, and would follow the current product-specific FDA label.

More in Growth Hormone

Growth Hormone

CJC-1295 DAC

Long-acting GHRH analog research designed to extend growth-hormone signaling over multiple days.

Read guide

Growth Hormone

CJC-1295 NO DAC + Ipamorelin

GHRH plus growth-hormone secretagogue research intended to support more pulsatile GH release.

Read guide

Growth Hormone

GHRP-2

Ghrelin-receptor agonist research focused on stimulating growth-hormone secretion.

Read guide